Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages 406-414

  Bidard, François Clément ^a,b   Peeters, Dieter J ^c,d   Fehm, Tanja ^e   Nolé, Franco ^f   Gisbert Criado, Rafael ^g   Mavroudis, Dimitrios ^h   Grisanti, Salvatore ⁱ   Generali, Daniele ^j   Garcia Saenz, Jose A ^k   Stebbing, Justin ^l   Caldas, Carlos ^m,n   Gazzaniga, Paola ^o   Manso, Luis ^p   Zamarchi, Rita ^q   de Lascoiti, Angela Fernandez ^r   De Mattos Arruda, Leticia ^s   Ignatiadis, Michail ^t   Lebofsky, Ronald ^a   van Laere, Steven J ^c,d,u   Meier Stiegen, Franziska ^e   Sandri, Maria Teresa ^f   Vidal Martinez, Jose ^g   Politaki, Eleni ^h   Consoli, Francesca ⁱ   Bottini, Alberto ^j   Diaz Rubio, Eduardo ^k   Krell, Jonathan ^l   Dawson, Sarah Jane ^m   Raimondi, Cristina ^o   Rutten, Annemie ^c   Janni, Wolfgang ^v   Munzone, Elisabetta ^f   Carañana, Vicente ^g   Agelaki, Sofia ^h   Almici, Camillo ⁱ   Dirix, Luc ^c,d   Solomayer, Erich Franz ^w   Zorzino, Laura ^f   Johannes, Helene ^x   Reis Filho, Jorge S ^b   Pantel, Klaus ^y   Pierga, Jean Yves ^a,z   Michiels, Stefan ^aa   more..

^a INSTITUT CURIE   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g HOSPITAL ARNAU DE VILANOVA   (Spain)

^h UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

ⁱ Department of Transfusion Medicine Laboratory for Stem Cells Manipulation and Cryopreservation   (Italy)

^j CREMONA HOSPITAL   (Italy)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o SAPIENZA UNIVERSITY OF ROME   (Italy)

^p HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^q VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^r Instituto de Investigación Sanitaria de Navarra   (Spain)

^s UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^t JULES BORDET INSTITUTE   (Belgium)

^u UNIVERSITY OF LEUVEN   (Belgium)

^v UNIVERSITY OF ULM   (Germany)

^w SAARLAND UNIVERSITY   (Germany)

^x INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^y UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^z UNIVERSITÉ PARIS DESCARTES   (France)

^aa INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ARTICLE; BLOOD LEVEL; BREAST METASTASIS; CANCER PROGNOSIS; CELL COUNT; CIRCULATING TUMOR CELL; HUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; VALIDITY;

AGED; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CELL COUNT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIKELIHOOD FUNCTIONS; MIDDLE AGED; MUCIN-1; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897445481     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70069-5     Document Type: Article

References (29)

1. Parkinson DR, Dracopoli N, Petty BG, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012, 10:138.
2. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
3. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
4. Medical devices. CellSearch Epithelial Cell Kit/CellSpotter Analyzer-K031588 US Food and Drug Administration, (accessed Feb 25, 2014). http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm081239.htm.
5. Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008, 19:891-897.
6. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009, 27:5153-5159.
7. Bidard F-C, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010, 21:1765-1771.
8. Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010, 17:199-204.
9. Consoli F, Grisanti S, Amoroso V, et al. Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. Tumori 2011, 97:737-742.
10. Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011, 31:979-984.
11. Pierga J-Y, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23:618-624.
12. Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012, 14:R118. the DETECT study group.
13. Martín M, Custodio S, de Las Casas M-LM, et al. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist 2013, 18:917-923.
14. Pierga J-Y, Bidard F-C, Cropet C, et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann Oncol 2013, 24:2999-3004.
15. Bidard F-C, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res 2012, 14:R29.
16. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
17. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011, 29:4273-4278.
18. Harrell FE, Lee KL, Mark DB Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
19. Anderson JR, Cain KC, Gelber RD Analysis of survival by tumor response. J Clin Oncol 1983, 1:710-719.
20. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012, 23:1144-1150.
21. Bidard F-C, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013, 32:179-188.
22. Smerage JB, Barlow WE, Hayes DF, et al. SWOG S0500-A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. 2013 San Antonio Breast Cancer Symposium, Dec 10-14, 2013. S5-07.
23. Lin NU, Thomssen C, Cardoso F, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22:203-210. the ESO-MBC Task Force.
24. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
25. Bidard F-C, Weigelt B, Reis-Filho JS Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013, 5:207ps14.
26. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011, 9(suppl 5):S1-32.
27. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
28. Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013, 31:2273-2281.
29. Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013, 73:2965-2975.